Description of the Evidence
BackgroundNatural history, incidence, and mortalityIn the United States in 2013, it is estimated that 12,340 cases of invasive cervical cancer will be diagnosed and that 4,030 women will die of the disease. These rates had been improving steadily. However, from 2005 to 2009, rates were stable in women younger than 50 years and decreased by 3.0% per year in women aged 50 years and older. From 2005 to 2009, mortality rates were stable among women of all ages. This improvement has been attributed largely to screening with the Papanicolaou (Pap) test.Invasive squamous carcinoma of the cervix results from the progression of preinvasive precursor lesions called cervical intraepithelial neoplasia (CIN), or dysplasia. CIN is histologically graded into mild dysplasia (CIN 1), moderate dysplasia (CIN 2), or severe dysplasia (CIN 3). Not all of these lesions progress to invasive cancer; many mild and moderate lesions regress. A further
Stage I Endometrial Cancer
Standard treatment options: A total hysterectomy and bilateral salpingo-oophorectomy should be done if the tumor: Is well or moderately differentiated.Involves the upper 66% of the corpus.Has negative peritoneal cytology.Is without vascular space invasion.Has less than a 50% myometrial invasion.Selected pelvic lymph nodes may be removed. If they are negative, no postoperative treatment is indicated. Postoperative treatment with a vaginal cylinder is advocated by some clinicians.For all other cases and cell types, a pelvic and selective periaortic node sampling should be combined with the total hysterectomy and bilateral salpingo-oophorectomy, if there are no medical or technical contraindications. One study found that node dissection per se did not significantly add to the overall morbidity from hysterectomy. While the radiation therapy will reduce the incidence of local and regional recurrence, improved survival has not been proven and toxic effects are
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Prevention
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Uterine Sarcoma Treatment
Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
What is prevention?
Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer,the number of new cases of cancer in a group or population is lowered. Hopefully,this will lower the number of deaths caused by cancer. To prevent new cancers from starting,scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a ...
General Information About Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus. GTD may be classified as follows:Hydatidiform mole (HM).Complete HM.Partial HM.Gestational trophoblastic neoplasia.Invasive mole.Choriocarcinoma.Placental-site trophoblastic tumor (very rare).Epithelioid trophoblastic tumor (even more rare).The reported incidence of GTD varies widely worldwide, from a low of 23 per 100,000 pregnancies (Paraguay) to a high of 1,299 per 100,000 pregnancies (Indonesia). However, at least part of this variability is caused by differences in diagnostic criteria and reporting. The reported incidence in the United States is about 110 to 120 per 100,000 pregnancies. The reported incidence of choriocarcinoma, the most aggressive form of GTD, in the United States is about 2 to 7 per 100,000 pregnancies. The U.S. age-standardized (1960 World Population Standard) incidence rate of choriocarcinoma is
Changes to This Summary (08 / 22 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
General Information About Cervical Cancer
Cervical cancer is a disease in which malignant (cancer) cells form in the cervix.The cervix is the lower, narrow end of the uterus (the hollow, pear-shaped organ where a fetus grows). The cervix connects the uterus to the vagina (birth canal). Anatomy of the female reproductive system. The organs in the female reproductive system include the uterus, ovaries, fallopian tubes, cervix, and vagina. The uterus has a muscular outer layer called the myometrium and an inner lining called the endometrium. Cervical cancer usually develops slowly over time. Before cancer appears in the cervix, the cells of the cervix go through a series of changes in which cells that are not normal begin to appear in the cervical tissue. When cells change from being normal cells to abnormal cells, it is called dysplasia. Depending on the number of abnormal cells, dysplasia may go away without treatment. The more abnormal cells there are, the less likely they are to go away. Dysplasia that is not treated may
Stage Information for Uterine Sarcoma
Definitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define carcinoma of the corpus uteri, which applies to uterine sarcoma; the FIGO system is most commonly used.[1,2]Uterine sarcomas include leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas. Table 1. Uterine SarcomaaStagea Adapted from FIGO Committee on Gynecologic Oncology.b Either G1, G2, or G3 (G = grade).c Endocervical glandular involvement only should be considered as stage I and no longer as stage II.d Positive cytology has to be reported separately without changing the stage.IbTumor confined to the corpus uteri.IAbNo or less than half myometrial invasion.IBbInvasion equal to or more than half of the myometrium.IIbTumor invades cervical stroma but does not extend beyond the uterus.cIIIbLocal and/or regional spread of the tumor.IIIAbTumor invades the serosa of the corpus uteri and/or